الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 129 |  |  |
| | | from | 129 | | |
Abstract
Liver fibrosis is the pathological process of excessive accumulation of ECM in the liver tissue leading to liver failure and even death.
RASinhibitors have proven to be safe and effective in the treatment of various fibrotic conditions, liver, lung and kidney fibrosis.
Recent reports also highlight the promising effect of using vitamin D in liver fibrosis.
The present study was designed to investigate the potential protective effectsof ARB(losartan), ACEI (captopril)and calcipotriol (non-calcemic analogue of the physiologically active metabolite of vitamin D3,lα,25-dihydroxycholecalciferol )on CCl4-inducedliver fibrosis and to identify the possible mechanisms that underliesuch protective effects.
To achieve these goals, in vivo studies were performed in male rats treated with CCl4in the absence and presence of losartan, captopril, or calcipotriol.